

**PATIENT INFORMATION LEAFLET**

**PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER**  
**Artesun® 60mg\***  
**Artesunate 60 mg for injection and sodium bicarbonate injection 50 mg/ml (1ml)**  
**and sodium chloride injection 9 mg/ml (5ml)**  
**for preparation of solution for intravenous or intramuscular injection**

**Read all of this leaflet carefully.**

- Keep this leaflet. You may need to read it again.
- If you have any further questions, please consult your health care provider
- This medicine is exclusively used in hospitals and clinics, and should only be administered by qualified medical personnel.

**In this leaflet:**

1. What is **Artesun® 60mg** and what it is used for
2. What you need to know before use of **Artesun® 60mg**
3. How **Artesun® 60mg** is used
4. Possible side effects of **Artesun® 60mg**
5. How to store **Artesun® 60mg**
6. Contents of the pack and other information

## **1. WHAT ARTESUN® 60MG IS AND WHAT IT IS USED FOR**

**Artesun® 60mg** contains artesunate and is for preparation of a solution for intravenous or intramuscular injection.

**Artesun® 60mg** is used for the treatment of severe *falciparum* malaria caused by the parasite *Plasmodium falciparum*.

## **2. WHAT YOU NEED TO KNOW BEFORE USE OF ARTESUN® 60MG**

**Artesun® 60mg should not be used**

If the patient is allergic to the active substance or any of the other ingredients of this product (see section 6).

### **Warnings and Precautions**

After intravenous or intramuscular treatment of the critical phase of the *falciparum* malaria infection, the patient will need to take oral medication to complete the treatment and avoid relapse.

---

\* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility. Throughout this WHOPAR the proprietary name is given as an example only.

Delayed haemolytic anaemia (a reduction of red blood cells) within the first month after treatment with Artesun has been reported, particularly in small children and travelers. The health care provider may therefore monitor the patient's blood count within 28 days after malaria therapy. If you feel excessively tired, weak or short of breath up to 4 weeks after treatment, inform your health care provider.

### **Taking other medicines**

Please inform the health care provider if the patient is taking or has recently taken any other medicines, including medicines bought without prescription

### **Pregnancy and breastfeeding**

#### **Pregnancy**

Severe malaria is especially hazardous during pregnancy, therefore full dose parenteral artesunate treatment should be administered at any stage of pregnancy without delay.

#### **Breastfeeding**

A small amount of the medicine enters human breast milk, but it will not protect the child from malaria. The health care provider will advise the patient on breast-feeding.

## **3. HOW ARTESUN® 60MG IS USED**

Artesunate may be injected intravenously (into a vein) or intramuscularly (into a muscle).

The duration of treatment is at least one day, and will be determined by the health care provider.

For each dose a new syringe and injection needle must be used. Further information on the method of administration for health care professionals is attached to this leaflet.

If you have any further questions on the use of this product, ask your health care provider.

## **4. POSSIBLE SIDE EFFECTS**

Like all medicines, **Artesun® 60mg** can cause side effects, but not everybody gets them. Some of these may be difficult to detect, and may be similar to effects of the disease itself.

### **Very common side effects (≥ 1/10):**

Post-treatment haemolytic anaemia (low red blood cells) in travellers and children, sometimes serious.  
Mild and transient decrease in reticulocyte count (blood elements important for clotting).

### **Common side effects (1/100-1/10):**

Dizziness, vomiting, light-headedness, headache, altered taste, abdominal pain or cramps, diarrhoea, rash, pain at injection site, insomnia, tinnitus (ringing in ears, with or without decrease in hearing), cough and / or nasal symptoms, nausea, hair loss, joint pain, bone and muscle disorders, fatigue, malaise, and fever.

### **Uncommon side effects (1/1000-1/100):**

Low red and white blood cell counts, clotting factor decreases, rises in liver enzymes, allergic reactions, heart rhythm and rate problems.

**Rare side effects (1/10,000-1/1000):**

Inflammation of the liver or pancreas. Bile stones. Artery narrowing, high blood pressure affecting the eyes.

**Very rare side effects (< 1/10,000):**

Severe reduction in red blood cells, tingling sensation and nerve pain.

**5. HOW TO STORE ARTESUN® 60MG**

**Artesun® 60mg** should be kept out of the sight and reach of children.

**Artesun® 60mg** is stored in the original packing, below 30° C, until it is ready to be used to create a solution. The reconstituted and diluted solutions should be stored below 30°C and the total in-use period should not exceed one hour.

Protect against direct sunlight. Do not store in a refrigerator or freezer.

The product must be destroyed if crystals or cloudiness are visible in the solution.

Do not use **Artesun® 60mg** after the date indicated by “EXP -----” on the immediate and the outer labelling.

**6. CONTENTS OF THE PACK AND OTHER INFORMATION**

**What Artesun® 60mg contains**

Artesunate powder for injection (no other excipients)

Solvent: sodium bicarbonate and water for injection

Diluent: sodium chloride and water for injection

**What Artesun® 60mg looks like and contents of the pack**

Artesunate for injection is a sterile white crystalline powder, 60 mg.

Sodium bicarbonate injection is a sterile clear colourless liquid, 50 mg/ml, 1 ml.

Diluent: Sodium chloride injection is a sterile clear colourless liquid, 9 mg/ml, 5 ml.

**Artesun® 60mg** is supplied in a carton box.

**Supplier and Manufacturer**

Guilin Pharmaceutical Co., Ltd.;

No. 43 Qilidian Road

Guilin,

Guangxi, China

Telephone: +86 773 3675053

Fax: +86 773 2670530

Email: [hem@guilinpharma.com](mailto:hem@guilinpharma.com)

For information about this medicinal product, please contact the supplier.

**This leaflet was drafted in November 2015.**

Section 4 was updated in January 2020.

Detailed information on this medicine is available on the World Health Organization (WHO) website:  
<https://extranet.who.int/prequal/>

---

This information is intended for healthcare professionals only:

## INFORMATION FOR HEALTHCARE PROFESSIONALS

### **Artesun® 60mg**

Artesunate for injection

Please refer to the Summary of Product Characteristics for full prescribing information.

### **Posology and method of administration**

#### ***Dose:***

*Adults and children weighing at least 20 kg: Artesun® 60mg* is administered at a dose of 2.4 mg of artesunate / kg body weight, by intravenous (IV) or intramuscular (IM) injection, at 0, 12 and 24 hours, then once daily until oral treatment can be substituted.

*Children weighing less than 20 kg: Artesun® 60mg* is administered at a dose of 3 mg of artesunate / kg body weight, by intravenous (IV) or intramuscular (IM) injection, at 0, 12 and 24 hours, then once daily until oral treatment can be substituted.

**Artesun® 60mg** should be administered for a minimum of 24 hours (3 doses), regardless of the patient's ability to tolerate oral medication earlier. After at least 24 hours of **Artesun® 60mg**, and when able to tolerate oral medication, the patient should be switched to a complete treatment course of an oral combination antimalarial regimen. Relevant treatment guidelines should be consulted when selecting an appropriate regimen (e.g. those of the WHO:

<http://www.who.int/malaria/publications/atoz/9789241549127/en>).

#### ***Preparation***

*Because of the instability of artesunate in aqueous solutions the reconstituted solution must be used within one hour of preparation. Therefore the required dose of artesunate should be calculated (dose in mg = patient's weight in kg x 2.4 or dose in mg = patient's weight in kg x 3 for children weighing less than 20 kg, respectively) and the number of vials of artesunate needed should be determined prior to reconstituting the artesunate powder.*

#### ***Reconstitution of the artesunate solution***

1. Using a syringe, withdraw 1 ml of the supplied sodium bicarbonate solvent from the ampoule
2. Inject the sodium bicarbonate into the vial containing the artesunate powder.
3. Shake the vial for several minutes to mix well until the powder is completely dissolved and the solution is clear. If the solution appears cloudy or a precipitate is present, it should be discarded.
4. The reconstituted artesunate solution should always be used immediately, and discarded if not used within one hour.

*Following reconstitution the solution must be diluted according to the method of injection, as described below.*

***Dilution for intravenous (IV) injection (10 mg/ml)***

1. Using a syringe, add 5 ml of sodium chloride 0.9% for injection to the vial containing the reconstituted artesunate solution. This will yield 6 ml of a solution containing artesunate 10 mg/ml.
2. Shake to mix well, ensuring that the resulting solution is still clear. If the solution appears cloudy or a precipitate is present, it should be discarded.  
The volume of the solution required (ml) will be:  
$$\text{Volume (ml)} = [\text{dose (mg)}] \div 10$$
3. Withdraw the required volume of artesunate solution from the vial with a syringe
4. Then inject slowly intravenously, over 1-2 minutes.

**Artesun® 60mg** should NOT be administered as an intravenous drip.

***Dilution for intramuscular (IM) injection (20 mg/ml)***

1. Using a syringe, add 2 ml of sodium chloride 0.9% for injection to the vial containing the reconstituted artesunate solution. This will yield 3 ml of a solution containing artesunate 20 mg/ml.
2. Shake to mix well, ensuring that the resulting solution is still clear. If the solution appears cloudy or a precipitate is present, it should be discarded.  
The volume of the solution required (ml) will be:  
$$\text{Volume (ml)} = [\text{dose (mg)}] \div 20$$
3. Withdraw the required volume of artesunate solution from the vial with a syringe and then inject intramuscularly; the anterior thigh is usually the preferred site for injection. If the total volume of solution to be injected intramuscularly is large, it may be preferable to divide the volume and inject it at several sites, e.g. both thighs.

*Do not use water for injection for reconstitution of the artesunate powder or for dilution of the resulting solution prior to injection.*